A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer

BACKGROUND: Strategies to improve activity of immune checkpoint inhibitors for triple-negative breast cancer (TNBC) are needed. Preclinical studies showed that antiangiogenic agents and poly (ADP-ribose) polymerase (PARP) inhibitors might sensitize tumors to immunotherapy. Here, we investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qingyuan, Shao, Bin, Tong, Zhongsheng, Ouyang, Quchang, Wang, Yuting, Xu, Guoying, Li, Shaorong, Li, Huiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528096/
https://www.ncbi.nlm.nih.gov/pubmed/36184642
http://dx.doi.org/10.1186/s12916-022-02527-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528096/
https://www.ncbi.nlm.nih.gov/pubmed/36184642
http://dx.doi.org/10.1186/s12916-022-02527-6

Ejemplares similares